Pharmacotherapies for Retinal Detachment.

[1]  John D Lambris,et al.  Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury , 2015, Science Translational Medicine.

[2]  H. Ahmadieh,et al.  Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial , 2015, Acta ophthalmologica.

[3]  Christopher J Brady,et al.  CLINICAL MANAGEMENT OF PROLIFERATIVE VITREORETINOPATHY: An Update , 2015, Retina.

[4]  S. Grisanti,et al.  A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. , 2014, Experimental eye research.

[5]  D. Zacks,et al.  Retinal cell death and current strategies in retinal neuroprotection , 2014, Current opinion in ophthalmology.

[6]  D. Eliott,et al.  Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? , 2014, Progress in Retinal and Eye Research.

[7]  N. Radke,et al.  Comment on ‘Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy’ , 2014, Eye.

[8]  Joan W. Miller,et al.  Photoreceptor cell death and rescue in retinal detachment and degenerations , 2013, Progress in Retinal and Eye Research.

[9]  C. Bunce,et al.  Ozurdex® (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial , 2013, Trials.

[10]  A. Capone,et al.  MICROPLASMIN (OCRIPLASMIN) IN PEDIATRIC VITREORETINAL SURGERY: Update and Review , 2013, Retina.

[11]  A. Wright,et al.  Long-term visual acuity and the duration of macular detachment: findings from a prospective population-based study , 2012, British Journal of Ophthalmology.

[12]  Zhi Zheng,et al.  Necrostatin-1 protects photoreceptors from cell death and improves functional outcome after experimental retinal detachment. , 2012, The American journal of pathology.

[13]  Mark W. Johnson,et al.  PARS PLANA VITRECTOMY WITHOUT ADJUVANT PROCEDURES FOR REPAIR OF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT , 2012, Retina.

[14]  F. Koerner,et al.  Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[15]  A. Wright,et al.  Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study , 2012, British Journal of Ophthalmology.

[16]  M. Gharbiya,et al.  CORRELATION BETWEEN SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT REPAIR , 2012, Retina.

[17]  Joan W. Miller,et al.  Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. , 2011, Investigative ophthalmology & visual science.

[18]  Joan W. Miller,et al.  Tauroursodeoxycholic Acid (TUDCA) Protects Photoreceptors from Cell Death after Experimental Retinal Detachment , 2011, PloS one.

[19]  Joan W. Miller,et al.  Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis , 2010, Proceedings of the National Academy of Sciences.

[20]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[21]  H. Ahmadieh,et al.  Effect of Oral Prednisolone on Visual Outcomes and Complications after Scleral Buckling , 2010, European journal of ophthalmology.

[22]  E. A. Chapin,et al.  Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. , 2010, Investigative ophthalmology & visual science.

[23]  D. Chen,et al.  Minocycline inhibition of photoreceptor degeneration. , 2009, Archives of ophthalmology.

[24]  E. A. Chapin,et al.  Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. , 2009, Investigative ophthalmology & visual science.

[25]  A. Hafezi-Moghadam,et al.  Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target , 2008, Proceedings of the National Academy of Sciences.

[26]  H. Ahmadieh,et al.  Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. , 2008, Ophthalmology.

[27]  D. Hu,et al.  Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. , 2008, American journal of ophthalmology.

[28]  Ying Han,et al.  Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. , 2008, Investigative ophthalmology & visual science.

[29]  T. Sakamoto,et al.  One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[30]  Michael D. Ober,et al.  Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. , 2007, A M A Archives of Ophthalmology.

[31]  G. Gettinby,et al.  Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors , 2007, Journal of cataract and refractive surgery.

[32]  C. Bunce,et al.  Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. , 2007, Ophthalmology.

[33]  C. Bunce,et al.  A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. , 2004, Ophthalmology.

[34]  Geoffrey P Lewis,et al.  The efficacy of delayed oxygen therapy in the treatment of experimental retinal detachment. , 2004, American journal of ophthalmology.

[35]  Arvydas Maminishkis,et al.  The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat. , 2002, Investigative ophthalmology & visual science.

[36]  C. Toth,et al.  Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits. , 2002, Investigative ophthalmology & visual science.

[37]  Atul Kumar,et al.  Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery , 2002, Clinical & experimental ophthalmology.

[38]  P. Khaw,et al.  Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. , 2001, Ophthalmology.

[39]  K Mervin,et al.  Limiting the proliferation and reactivity of retinal Müller cells during experimental retinal detachment: the value of oxygen supplementation. , 1999, American journal of ophthalmology.

[40]  K Mervin,et al.  Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation. , 1999, American journal of ophthalmology.

[41]  P. Wiedemann,et al.  Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. , 1998, American journal of ophthalmology.

[42]  G. Lewis,et al.  Alkylphosphocholines: a new approach to inhibit cell proliferation in proliferative vitreoretinopathy. , 2009, Developments in ophthalmology.